Viral Vector Manufacturing Market Forecasts to 2028 – Global Analysis By Type (Pox Virus, Cytomegalovirus, Herpes Simplex Virus Vectors, Adenoviral Vectors), Application (Gene Therapy, Vaccinology) and By Geography

Viral Vector Manufacturing Market Forecasts to 2028 – Global Analysis By Type (Pox Virus, Cytomegalovirus, Herpes Simplex Virus Vectors, Adenoviral Vectors), Application (Gene Therapy, Vaccinology) and By Geography

According to Stratistics MRC, the Global Viral Vector Manufacturing Market is accounted for $668.48 million in 2022 and is expected to reach $1,804.59 million by 2028 growing at a CAGR of 18.0% during the forecast period. Viral vectors are manufactured for delivering genetic materials into the target cells in various genetic, vaccinology, and molecular biology applications. Also, viral vectors are exploited for discovering various therapeutic areas. Viral vectors are manufactured using viruses and animal or insect cell cultures.

There were over 9.5 thousand active drugs of chemical, synthetic origin, thus making it the top origin for pipeline drugs in terms of number of active drugs. The past five years have seen viral-vector-based gene therapies become a reality. To date, eight therapies have been approved by the US Food and Drug Administration (FDA) across three different types of viral vectors: adeno-associated virus (AAV), lentivirus, and herpes simplex virus. With 25 viral-vector therapeutics in late-stage development and another 120 in Phase II trials as of February 2022, the number of approved therapies is only expected to grow.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The growing worldwide burden of cancer, infectious diseases, and genetic disorders is increasing in several countries and therefore acting as the biggest driver of the market. Factors driving market growth include the increasing prevalence of genetic diseases, cancer, and infectious diseases, the increasing number of clinical trials of viral vectors, and the availability of funding for gene therapy development. The Viral Vector Manufacturing Market is growing significantly due to a rise in the number of gene therapy-based products in the market.

Restraint:

Short life of viral vectors

Viral vectors come with the disadvantage of having a short life. This is expected to have a negative impact on the growth of the market. Moreover, the high cost of gene-based medical therapies might hamper the demand for viral vectors during the forecast period.

Opportunity:

Emergence of molecular biology

The emergence of molecular biology is accelerating genomic sequencing that is further expected to reinforce precision medicine. The progress showcased by molecular biology and medical science are aligning gene therapy to a progressive borderline, thereby fostering the growth of the viral vector manufacturing for revolutionizing patient care. Moreover, with their increasing use in gene therapy for the treatment of several diseases such as cancer, metabolic diseases, and others, the demand for viral vector manufacturing is projected to rise.

Threat:

Highly regulated processes

Tedious and highly regulated processes for vector production and inadequate capacity for vector production are some of the key challenges in the market for viral vectors and plasmid DNA manufacturing. To overcome these challenges, more focused attempts are required.

The vaccinology segment is expected to be the largest during the forecast period

High employment of viral vectors in vaccine development owing to their efficiency-related advantages is the main factor driving the vaccinology sector. Some advantages are the potential to elicit a wide immune response, safety profiles, and easy manufacturing. The recent outbreak of the COVID-19 virus has driven the use of viral vectors in vaccine development. Although viral vectors were widely used for vaccine development before the emergence of COVID-19, the urgency to develop a vaccine against this virus has led the scientific community to repurpose the existing approaches. Non-replicating viral vectors are being used in the COVID-19 viral vector vaccines. Various companies have launched platforms for the clinical trial base manufacturing for addressing the bottlenecks associated with the viral vector supply chain amidst the pandemic situation. Such initiatives are attributive to drive manufacturing and research practices in viral vector academic organizations and CROs .

The research institutes segment is expected to have the highest CAGR during the forecast period

The increasing involvement of the research community in gene and cell therapy research activities is expected to increase the demand for viral vectors in the global market. An increase in the introduction of advanced therapies along with the rising number of gene therapy-based R&D programs by companies, pharmaceutical, and biopharmaceutical companies are emerging as the significant end-users of the market for viral vectors and plasmid DNA manufacturing. For instance, Abeona Therapeutics is one of such companies that is actively evaluating AAV9-based gene therapies for CLN1 and CLN3 diseases.

Region with largest share:

North America is projected to hold the largest market share owing to the high adoption rate of new therapies and the high incidence rate of cancer. The increasing prevalence of genetic and other chronic disorders, an aging population, growing demand for targeted and personalized medicine, and favorable government initiatives are the factors responsible for future market growth in the region. Many companies have been expanding their facilities and investing a significant amount of capital in the region. Educational and academic institutes have also been at the forefront of R&D investment. For instance, Harvard University announced that it was collaborating with contract development and manufacturing organizations (CDMOs) to develop a USD 50 million cell and viral vector manufacturing facility. Such initiatives are expected to boost the market growth in North America.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the increasing research activities for the introduction of novel gene therapies in the untapped markets of this region. The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia Pacific viral vector manufacturing market. The viral vector manufacturing market is also driven by the government approvals to conduct trials related to the Ebola virus disease vaccine. An increasing number of clinical trials related to viral vector vaccine in China also drives the growth of the viral vector manufacturing market in this country.

Key players in the market

Some of the key players profiled in the Viral Vector Manufacturing Market include Merck KGaA, Thermo Fisher Scientific Inc., Brammer Bio, Spark Therapeutics, Fujifilm Holdings Corporation, Lonza, Kaneka Eurogentec, Finvector Vision Therapies, Cobra Biologics, Uniqure, Oxford Biomedica, Massbiologics, Novasep, Regenxbio, and Shape Therapeutics.

Key developments:

In January 2021: Thermo Fisher Scientific acquired Viral Vector’s manufacturing business of Henogen SA, Novasep’s in Belgium, for approximately EUR 725 million.

In January 2021: Fujifilm Corporation announced plans to invest USD 40 million, which will be used to establish a new processing facility for viral vector manufacturing and associated research.

In December 2020: Shape Therapeutics launched an innovative capsid discovery platform designed to improve the delivery and safety of gene therapies. The platform could generate adeno-associated virus (AAV) vectors that are tissue-specific.

In April 2020: Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility.

Diseases Covered:
• Human Disease
• Veterinary Disease

Types Covered:
• Pox Virus
• Cytomegalovirus
• Herpes Simplex Virus Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retroviral Vectors

Applications Covered:
• Gene Therapy
• Vaccinology

End Users Covered:
• Biotech Companies
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances